Sun BioPharma Inc. said that Dalvir Gill has resigned from the company's board, effective Aug. 30.
The company said in a Sept. 6 filing that Gill resigned in order to focus on other responsibilities.
Gill joined the board of the Waconia, Minn.-based biotechnology company as an independent director in March 2016. He has served as the CEO of TransCelerate BioPharma Inc. since January 2013.
Sun BioPharma develops disruptive therapeutics for severe unmet medical needs. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer.